Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations.
Mol Ther Nucleic Acids. 2022 Aug 13;29:733-748. doi: 10.1016/j.omtn.2022.08.016. eCollection 2022 Sep 13.
Mol Ther Nucleic Acids. 2022.
PMID: 36090755
Free PMC article.
Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy.
Trochet D, Prudhon B, Mekzine L, Lemaitre M, Beuvin M, Julien L, Benkhelifa-Ziyyat S, Bui MT, Romero N, Bitoun M.
Trochet D, et al. Among authors: mekzine l.
Mol Ther Nucleic Acids. 2022 Feb 13;27:1179-1190. doi: 10.1016/j.omtn.2022.02.009. eCollection 2022 Mar 8.
Mol Ther Nucleic Acids. 2022.
PMID: 35282416
Free PMC article.
Item in Clipboard
Cite
Cite